NESS ZIONA, Israel, March 25, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that its U.S. commercialization partner, Galderma, will be promoting TWYNEO (tretinoin and benzoyl peroxide) Cream, 0.1%/3% at the American Academy of Dermatology (AAD) Annual Meeting, March 25-29, 2022, in Boston, Massachusetts. TWYNEO Cream is the first and only tretinoin and benzoyl peroxide 2-in-1 combination proven to treat moderate-to-severe acne.1,2 Patented microencapsulation technology unites two ingredients that previously could never be combined and enables their slow release to deliver visible results in as little as two weeks.2-4
Sol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO® at the American Academy of Dermatology Annual Meeting to be Held March 25-29 in Boston, MA
Globe Newswire -
Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
